A. Schafer

Broadly neutralizing antibody induction by non-stabilized SARS-CoV-2 Spike mRNA vaccination in nonhuman primates

Non-stabilized SARS-CoV-2 Spike mRNA vaccination in macaques induces B cell lineages targeting conserved epitopes on Omicron variants or cross-neutralizing epitopes on Sarbecoviruses.

Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe disease

The paper identifies broadly neutralizing antibodies targeting the S2 region of betacoronavirus spikes that protect against SARS-CoV-1, SARS-CoV-2, and MERS-CoV.

Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in mice.

This paper evaluates the therapeutic efficacy of GS-621763, an oral prodrug of remdesivir, against SARS-CoV-2 in mice, showing reduced viral load and improved lung function.

Targeted isolation of panels of diverse human protective broadly neutralizing antibodies against SARS-like viruses

This study isolates a panel of broadly neutralizing antibodies against SARS-like viruses from donors, showing effectiveness against multiple variants including Omicron.

Common Mechanism of SARS-CoV and SARS-CoV-2 Pathogenesis across Species

The paper identifies host susceptibility loci for SARS-CoV and SARS-CoV-2 using GWAS and Collaborative Cross datasets, validating CCR9 as a key regulator of severe disease outcomes across species.

The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates

This study examines SARS-CoV-2 neutralizing and infection-enhancing antibodies, showing in vitro enhancement does not always lead to in vivo disease enhancement, but can cause increased lung inflammation in monkeys.

Baseline T cell immune phenotypes predict virologic and disease control upon SARS-CoV infection

The paper shows that baseline T cell immune signatures in mice predict virologic and disease outcomes upon SARS-CoV infection.

SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness

This paper describes the development of an mRNA vaccine (mRNA-1273) against SARS-CoV-2, showing it induces neutralizing antibodies and CD8 T cell responses and protects mice from infection.

Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals

The paper identifies potent neutralizing antibodies against SARS-CoV-2 that block receptor binding and protect animals, providing insights for vaccine and therapy development.

A mouse-adapted SARS-CoV-2 model for the evaluation of COVID-19 medical countermeasures

This paper develops a mouse-adapted SARS-CoV-2 model to evaluate medical countermeasures, showing age-related disease severity and the efficacy of IFN lambda-1a.